Adalimumab biosimilar (Samsung Bioepis)

阿达木单抗生物类似药（三星Bioepis）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (Samsung Bioepis)
Drug Alias Name阿达木单抗生物仿制药（三星Bioepis）Adalimumab-bwwdadalimumab biosimilarImraldiHadlima +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPediatric ulcerative colitisPsoriasis +[12] 
Global Approved IndicationsPlaque psoriasisPediatric ulcerative colitisPsoriasis +[12] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2017/08/24
Country/TerritoryBelgiumUnited StatesPoland +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiogen IncMerck & Co IncSamsung Bioepis Nl Bv +[5] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPediatric ulcerative colitisPsoriasis +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A